SPECIAL COMMENTARIESMetastasectomy in patients with renal cell carcinoma: when and how?Omid, Saraa; Abufaraj, Mohammada,b; Remzi, MesutaAuthor Information aDepartment of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria bDepartment of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan Correspondence to Mesut Remzi, Department of Urology, Vienna General Hospital of Vienna, Medical University, Währinger Gürtel 18-20, 1090 Vienna, Austria. Tel: +43 14040026150; e-mail: Mesut.firstname.lastname@example.org Current Opinion in Urology: July 2020 - Volume 30 - Issue 4 - p 602-609 doi: 10.1097/MOU.0000000000000768 Buy Metrics Abstract Purpose of review The role of metastasectomy in the management of metastatic renal cell carcinoma (mRCC) remains controversial. The aim of this review is to summarize and evaluate the recent findings about the surgical treatment of patients with mRCC focusing on the literature published in the last 2 years. Recent findings Despite the lack of randomized controlled trials, the benefit of metastasectomy in term of cancer-specific and overall survival have been demonstrated in large observational studies. Results of ongoing clinical trials evaluating the impact of combination of surgical and systemic therapies are eagerly awaited and may shed the light on a new treatment armamentarium in this subset of patients. Summary Several novel systemic agents have emerged and is continuously changing the treatment paradigm in patients with advanced RCC. However, surgical resection of the primary tumor and metastatic deposits represents a definitive cure option in well selected patients. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.